ACRO Biomedical’s Collagen Ophthalmic Matrix Receives Approval from Taiwan’s Ministry of Health and Welfare

A Breakthrough for Corneal Transplant Patients

ACRO Biomedical Co., Ltd. (Stock Code: 6748) announced today that its Collagen Ophthalmic Matrix has successfully obtained approval from Taiwan’s Ministry of Health and Welfare (MOHW), with registration number MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and offers new hope to millions of patients worldwide awaiting corneal transplants.

Bridging the Corneal Transplantation Gap

According to the World Health Organization (WHO), over 20 million people worldwide suffer from corneal blindness due to injury or infection. However, only about 100,000 corneal transplants are performed annually, leaving a massive gap between supply and demand. A report from Global Market Insights, Inc. estimates that the global corneal transplant market will reach $500 million in 2024, with a projected growth to $1 billion by 2033, driven by a 7.59% compound annual growth rate (CAGR) from 2025 to 2033.

Revolutionary Technology for Regenerative Corneal Solutions

ACRO Biomedical’s ABCcolla® Collagen Ophthalmic Matrix is developed using supercritical CO₂ decellularization technology, which removes all cells and impurities from animal-derived corneal tissue while preserving the complete collagen scaffold structure. This innovative process ensures excellent biocompatibility, biodegradability, and tissue regeneration capability.

The product has received patents in 15 countries and was awarded the Silver Medal at the 2023 National Biotechnology and Medicine Care Award. Notably, there are currently no equivalent products available on the Taiwan market.

A Safe and Effective Alternative to Donor Corneas

ACRO Biomedical’s ABCcolla® Collagen Ophthalmic Matrix is derived from porcine corneas, which have similar size and structural properties to human corneas. By removing all porcine corneal cells, the product serves as a viable alternative to human donor corneas, with a lower risk of rejection.

Following years of rigorous clinical trials, this collagen ophthalmic matrix is now approved for use in corneal reconstruction procedures, benefiting patients suffering from corneal melting, trauma, infections, and other severe corneal injuries. It can be used as a corneal graft substitute in a variety of transplant and reconstruction surgeries.

A Vision for the Future

ACRO Biomedical is now preparing for the commercial launch of the product to meet market demand and improve patients’ quality of life.

Dr. Dar-Jen Hsieh, Chairman and CEO of ACRO Biomedical, stated:

“Our vision is to solve the global shortage of tissues and organs, ensuring that every patient in need of a corneal transplant receives timely treatment. This approval is not just a recognition of our technology but a beacon of hope for patients awaiting transplantation.”

Leading the Future of Regenerative Ophthalmology

With the aging global population, the rising prevalence of corneal diseases, and increasing awareness of vision care, the demand for corneal transplants and related medical solutions is expected to rise significantly.

Through the expansion and adoption of this groundbreaking technology, ACRO Biomedical aims to reduce dependence on donor corneas, giving more patients the chance to regain their sight. The company remains committed to continuous innovation in regenerative medicine, striving to become a global leader in the field.

 

Spokesperson:
Dr. Dar-Jen Hsieh, Chairman & CEO